Coeptis Financial Statements From 2010 to 2024

COEPW Stock  USD 0.02  0.00  0.00%   
Coeptis Therapeutics financial statements provide useful quarterly and yearly information to potential Coeptis Therapeutics Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Coeptis Therapeutics financial statements helps investors assess Coeptis Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Coeptis Therapeutics' valuation are summarized below:
There are over one hundred eighteen available fundamental signals for Coeptis Therapeutics Holdings, which can be analyzed over time and compared to other ratios. All traders should should validate Coeptis Therapeutics' prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 40.1 M in 2024, whereas Enterprise Value is likely to drop slightly above 18.9 M in 2024.
Check Coeptis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coeptis Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.4 K, Other Operating Expenses of 41.3 M or Total Operating Expenses of 41.3 M, as well as many indicators such as Price To Sales Ratio of 5.2 K, Dividend Yield of 0.0 or PTB Ratio of 4.43. Coeptis financial statements analysis is a perfect complement when working with Coeptis Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Coeptis Therapeutics Correlation against competitors.
For more information on how to buy Coeptis Stock please use our How to Invest in Coeptis Therapeutics guide.

Coeptis Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.6 M9.1 M2.3 M
Slightly volatile
Short and Long Term Debt Total1.6 MM863.6 K
Slightly volatile
Total Current LiabilitiesM2.1 MM
Slightly volatile
Accounts Payable84.7 K89.1 K150 K
Pretty Stable
Cash4.6 M4.4 MM
Slightly volatile
Non Current Assets Total2.4 M4.6 M1.1 M
Slightly volatile
Cash And Short Term Investments4.6 M4.4 MM
Slightly volatile
Common Stock Shares Outstanding9.4 M16.4 M10.5 M
Slightly volatile
Liabilities And Stockholders Equity9.6 M9.1 M2.3 M
Slightly volatile
Total Liabilities2.7 M3.6 M1.4 M
Slightly volatile
Total Current Assets4.8 M4.5 MM
Slightly volatile
Short Term Debt1.3 M1.8 M696.5 K
Slightly volatile
Intangible Assets37.2 K41.9 K45.6 K
Slightly volatile
Common Stock1.7 K1.8 K16 K
Slightly volatile
Current Deferred Revenue1.2 M1.1 M359 K
Slightly volatile
Other Current Liabilities259.1 K163.8 K590.5 K
Slightly volatile
Property Plant And Equipment Net68.3 K82.2 K71 K
Pretty Stable
Other Assets0.80.90.98
Slightly volatile
Long Term Debt128.2 K135 K247.6 K
Pretty Stable
Non Current Liabilities Total1.2 M1.5 M496.2 K
Slightly volatile
Capital Lease Obligations62.3 K99.2 K56.8 K
Pretty Stable
Other Current Assets123.4 K163.7 K76.1 K
Slightly volatile
Property Plant And Equipment Gross91.7 K122.8 K84 K
Pretty Stable
Short and Long Term Debt1.4 M975 K1.8 M
Slightly volatile
Capital Stock3.2 K3.5 K2.7 K
Slightly volatile

Coeptis Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization719.4 K901.2 K597.4 K
Pretty Stable
Other Operating Expenses41.3 M39.3 M13.1 M
Slightly volatile
Total Operating Expenses41.3 M39.3 M12.4 M
Slightly volatile
Interest Expense212.3 K251.2 K166.6 K
Slightly volatile
Selling General Administrative24.3 M39.3 M11.7 M
Slightly volatile
Selling And Marketing Expenses7.2 K9.6 K6.7 K
Pretty Stable
Cost Of Revenue939 K1.2 M943 K
Very volatile
Reconciled Depreciation762.7 KM451.4 K
Slightly volatile

Coeptis Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow4.6 M4.4 MM
Slightly volatile
Begin Period Cash Flow2.6 M2.5 M622.9 K
Slightly volatile
Depreciation762.7 K1.2 M461.4 K
Slightly volatile
Issuance Of Capital StockM3.5 M2.2 M
Slightly volatile
Dividends Paid62.1 K69.8 K76 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.2 K3.1 K5.9 K
Slightly volatile
Days Sales Outstanding207233253
Slightly volatile
Average Payables93.2 K104.9 K114.2 K
Slightly volatile
Stock Based Compensation To Revenue20.2422.7724.795
Slightly volatile
Capex To Depreciation0.00.03.1291
Slightly volatile
EV To Sales5.3 K3.2 K5.9 K
Slightly volatile
Payables Turnover0.670.70521.4238
Slightly volatile
Sales General And Administrative To Revenue150169184
Slightly volatile
Research And Ddevelopement To Revenue0.0960.10.1129
Slightly volatile
Capex To Revenue18.6621.022.8662
Slightly volatile
Cash Per Share0.05430.05720.0466
Pretty Stable
Days Payables Outstanding351518518
Slightly volatile
Income Quality0.320.340424.3247
Slightly volatile
Intangibles To Total Assets0.720.360.3913
Pretty Stable
Current Ratio1.841.75650.4414
Slightly volatile
Receivables Turnover1.131.271.3837
Slightly volatile
Graham Number1.681.7685143
Slightly volatile
Average Receivables24.7 K23.5 K6.7 K
Slightly volatile
Revenue Per Share0.00210.00330.002
Slightly volatile
Interest Debt Per Share0.03760.03963.4429
Slightly volatile
Debt To Assets0.130.13941.1308
Very volatile
Days Of Payables Outstanding351518518
Slightly volatile
Quick Ratio1.841.75650.442
Slightly volatile
Net Income Per E B T0.780.980.8229
Slightly volatile
Cash Ratio0.420.49160.2566
Slightly volatile
Days Of Sales Outstanding207233253
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.311.151.3425
Slightly volatile
Fixed Asset Turnover1.112.120.8352
Slightly volatile
Debt Ratio0.130.13941.1308
Very volatile
Price Sales Ratio5.2 K3.1 K5.9 K
Slightly volatile
Asset Turnover0.01210.01270.0782
Slightly volatile
Operating Cycle191215234
Slightly volatile

Coeptis Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.1 M20.1 M145.8 M
Slightly volatile
Enterprise Value18.9 M19.9 M145.4 M
Slightly volatile

Coeptis Fundamental Market Drivers

Cash And Short Term Investments3.8 M

About Coeptis Therapeutics Financial Statements

Coeptis Therapeutics investors use historical fundamental indicators, such as Coeptis Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Coeptis Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1.2 M
Cost Of Revenue1.2 M939 K
Stock Based Compensation To Revenue 22.77  20.24 
Sales General And Administrative To Revenue 169.42  150.32 
Research And Ddevelopement To Revenue 0.10  0.10 
Capex To Revenue 21.00  18.66 
Ebit Per Revenue(168.55)(176.98)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Coeptis Stock Analysis

When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.